Leonardo DRS heads into its July 30 earnings date down 8.6% over the past month, yet the short-selling community is quietly exiting rather than pressing the thesis — the real story is whether the stock's valuation can hold at current levels if margin pressure persists.
Short interest has continued the retreat flagged in last week's note. It now stands at 1.14% of free float, down 7.5% in share terms over the past week and nearly 14% over the past month. That brings the total shorted position to roughly 3 million shares — a fraction of what the borrow market can supply. Availability is essentially unconstrained, with over 138 million shares available to lend against a shorted position that size; the lending market is nowhere near stressed. Cost to borrow has crept up 9% on the week to 0.73%, its highest in 30 days, but that still represents a trivially cheap borrow for anyone who wants it. The ORTEX short score has dipped again to 35.8, its lowest reading in the past two weeks, meaning bearish conviction is still fading, not building. Options traders are equally relaxed — the put/call ratio of 0.29 is barely a whisker above its 20-day average of 0.28, and well off the 0.64 peak seen earlier in the year. This is not a stock where fear is being priced.
The Street remains constructive in direction, though the most recent formal analyst activity is now dated. BofA raised its target to $55 back in March, and Canaccord lifted to $54 after Q1 results in May — both maintaining Buy ratings. Morgan Stanley holds at Equal-Weight with a $47 target, representing a slight discount to current levels. The consensus mean target of $52.90 implies roughly 19% upside from the current $44.37 close, which is a reasonable cushion, but those targets were set before the stock gave back its spring gains. The bull case centers on the record $8.9 billion backlog and a 24% surge in Advanced Sensing funded bookings. Bears point to the EBITDA margin compression to 12.2%, elevated R&D drag, and Germanium supply chain exposure — headwinds management has flagged as likely to persist into the back half of the year. At a PE of roughly 33.8x and EV/EBITDA near 21.9x, the valuation reflects confidence in the backlog converting cleanly. The EPS surprise factor score at 72 out of 100 suggests the company has a reasonable track record of beating estimates, but the 30-day EPS momentum score of just 29 hints that near-term estimate revisions have been heading in the wrong direction.
The ownership picture is worth one observation. Parent Leonardo S.p.A. holds 71% of the company — a structural anchor that shapes how freely the float can move. Among the external shareholders, several active managers added meaningfully in recent quarters: T. Rowe Price built a position of over 840,000 new shares, Voya added 1.55 million shares, and State Street added 384,000 as recently as June 30. These are additions, not trims, which at least partially offsets the insider selling picture. CEO John Baylouny sold just over 36,000 shares at $45.67 on June 18, while the CFO sold around 8,300 shares at $46.48 on June 8. Neither transaction is large relative to the company's outstanding shares, and both carry a trade significance score of 2 out of 10, but the cluster of executive sales just above current price levels is a data point the market is unlikely to ignore as the stock sits at $44.37.
Peer context is modestly negative for the week. MRCY fell 13.4% over the same period — a sharper move than DRS's 2.4% decline — while LHX and NOC each slipped 1.8% and 3.7% respectively. The relative resilience of DRS suggests the stock is not being dragged indiscriminately lower with the sector, even as it gives back its spring highs.
The July 30 print is now the clear focus. Based on the two most recent earnings events, DRS moved -2.4% on the day after its May 2026 result but recovered 4.8% over the five days that followed. The prior Q results saw a 4.5% one-day gain extending to 7.2% over five days. The asymmetry in those reactions suggests the market has tended to reward DRS on earnings — but the margin compression narrative has grown louder since those prints, and the question heading into July 30 is less about whether bookings are strong and more about whether EBITDA guidance for the second half can hold above the 12% floor.
See the live data behind this article on ORTEX.
Open DRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
